Cardiac surgery and the coagulation system

Current Opinion in Anaesthesiology

Volumn 13, Issue 1, 2000, Pages 27-34

  Dietrich, Wulf ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; FIBRIN; HEPARIN; RECOMBINANT HIRUDIN; THROMBIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; GRAFT OCCLUSION; HEART SURGERY; HEMOSTASIS; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0034061527     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200002000-00005     Document Type: Review

References (50)

1. 1 Boyle EM, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997; 63:277-284.
2. 2 Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82:3350-3357.
3. 3 Verrier ED, Morgan EN. Endothelial response to cardiopulmonary bypass surgery. Ann Thorac Surg 1998; 66:S17-S19. This article reviews the function of the endothelium and the pathological conditions that occur in response to CPB. Strategies to block single cytokines, or adhesion molecules involved in endothelial dysfunction, are discussed. Monoclonal antibodies to block neutrophil adhesion were applied in a baboon model, and attenuation of gene activity on the transcriptional level was evaluated.
4. 4 Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998; 62:1817-1824. This review describes the link between inflammation and coagulation. The central role of thrombin in activating coagulation and fibrinolysis and the feedback activation of inflammation is characterized. The author depicts the interaction of the protein C pathway and its inhibition by tumour necrosis factor-χ.
5. 5 Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998; 66:2135-2144. The inflammatory response initiated by CPB is characterized by the interaction between activated leucocytes, platelets, plasmatic coagulation factors and endothelial cells. This process is mediated by the expression of three main groups of adhesion molecules: the selectins, the integrins and the immunoglobulin superfamily. These interactions are described in this review and possible interventions in the inflammatory response are discussed.
6. 6 Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998; 65:712-718.
7. 7 Parratt R, Hunt BJ. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass. Br J Haematol 1998; 101:40-46. A significant increase in total procoagulant activity on circulating monocytes after start of CPB was demonstrated. Direct activation of factor X through the monocyte CD11b occurs during CPB and appears to contribute to thrombin generation during CPB. This study emphasizes the important role of monocytes in the haemostatic activation during CPB.
8. 8 Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, vanOeveren W, Ebels T. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg 1999; 67:1370-1375. This study descibes the interesting phenomenon of increased postoperative haemostatic activation even after off-pump surgery. The patterns of this activation are similar to those seen in acute coronary syndromes. Adverse coronary events occur mainly during this postoperative period. A relationship between adverse events and haemostatic activation is possible, but not yet proved.
9. 9 Mannucci L, Gerometta PS, Mussoni L, Antona C, Parolari A, Salvi L, et al. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin. Thromb Haemost 1995; 73:356-361.
10. 10 Wolman RL, Nussmeier NA, Aggarwal A, Kanchuger MS, Roach GW, Newman MF, et al. Cerebral injury after cardiac surgery: identification of a group at extraordinary risk. Multicenter Study of Perioperative Ischemia Research Group (McSPI) and the Ischemia Research Education Foundation (IREF) Investigators. Stroke 1999; 30:514-522.
11. 11 Bates ER. Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes. Semin Thromb Hemost 1997; 23:575-581.
12. 12 Gu YJ, deVries AJ, Vos P, Boonstra PW, van Oeveren W. Leukocyte depletion during cardiac operation: a new approach through the venous bypass circuit. Ann Thorac Surg 1999; 67:604-609.
13. 13 Sevan DH: Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999; 104:208-219.
14. 14 Slaughter TF, Lebleu TH, Douglas JM, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80:520-526.
15. 15 Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82:P12-P18.
16. 16 Bates SM, Weitz JI. Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc Res 1999; 41:418-432. Similarities exist between acute coronary syndromes and activation of haemostasis during and after CPB. This review describes the pathophysiology of acute coronary syndromes and the effect of direct thrombin inhibitors. Direct thrombin inhibitors only block thrombin activation and not its generation. The short-term benefits of these drugs during the acute event are lost over time, suggesting that long-term therapy is necessary. Because CPB is a short-term event, improved anticoagulation may be possible with these drugs.
17. 17 Yusuf S, Pogue J, Anand S, Flather M, Fox K, Tognoni G, et al. Effects of recombinant hirudin (Lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353:429-438.
18. 18 Greinacher A, Volpel H, Janssens U, HachWunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (Lepirndin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80. This study evaluates the efficacy of recombinant hirudin for anticoagutation in patients with confirmed HIT. Of special interest, eight patients with hirudin anticoagulation during CPB are described. This is the first major prospective study of HIT patients to assess the efficacy of hirudin anticoagulation. Because a prospective control group was not feasible for ethical reasons, the patients were compared with a historical control group.
19. 19 Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzlufft F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998; 89:777-780. This is the first report of hirudin anticoagulation during CPB in patients with HIT. The management of five patients with documented HIT is described. Four patients survived uneventfully, and one patient developed intraoperative and postoperative haemorrhage and died. Hirudin management is described in detail.
20. 20 Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77:920-925.
21. 21 Spanier TB, Chen JM, Oz MC, Edwards NM, Kisiel W, Stern DM, et al. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 116:860-869.
22. 22 Kozek-Langenecker SA, Wanzel O, Berger R, Kettner SC, Coraim F. Increased anticoagulation during cardiopulmonary bypass by prostaglandin E-1. Anesth Analg 1998; 87:985-988.
23. 23 Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196:436-440.
24. 24 Gibbs NM, Weightman WM, Thackray NM, Michalopoulos N. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. J Cardiothorac Vasc Anesth 1998; 12:536-541.
25. 25 Boldt J, Walz G, Triem J, Suttner S, Kumle B. Point-of-care (POC) measurement of coagulation after cardiac surgery. Intens Care Med 1998; 24:1187-1193.
26. 26 Zalunardo MP, Zollinger A, Seiferf B, Patti M, Pasch T. Perioperative reliability of an on-site prothrombin time assay under different haemostatic conditions. Br J Anaesth 1998; 81:533-536.
27. 27 Dietrich GV, Schueck R, Menges T, Kiesenbauer NP, Fruehauf AC, Marquardt I. Comparison of four methods for the determination of platelet function in whole blood in cardiac surgery. Thromb Res 1998; 89:295-301.
28. 28 Miyashita T, Kuro M. Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Anesth Analg 1998; 87:1228-1233.
29. 29 Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 (TM) system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
30. 30 Francis J, Francis D, Larson L, Helms E, Garcia M. Can the platelet function analyzer (PFA (R))-100 test substitute for the template bleeding time in routine clinical practice? Platelets 1999; 10:132-136.
31. 31 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, VelaCantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312-319.
32. 32 Shore-Lesserson L, Ammar T, DePerio M, Vela-Cantos F. Platelet-activated clotting time does not measure platelet reactivity during cardiac surgery. Anesthesiology 1999; 91:362-368. A prospective comparison of platelet-activated clotting time with platelet reactivity as measured by flow cytometry. Changes in platelet-activated clotting time did not correlate with expression of P-selectin. Additionally, 8 h chest tube drainage did not correlate with platelet-activated clotting time. This test is not a specific measure of platelet reactivity and does not predict bleeding.
33. 33 Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery-a review of current and emerging techniques. Anesthesiology 1999; 91:1122-1151. An extensive overview of anticoagulation monitoring during cardiac surgery.
34. 34 Munoz JJ, Birkmeyer NJO, Birkmeyer JD, O'Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999; 99:81-89. This meta-analysis was performed to compare the relative effectiveness and adverse effect profiles of two antifibrinolytic drugs. Fifty-two randomized trials were included (aprotinin n=46; ε-aminocaproic acid n=9). Both drugs reduced bleeding tendency, but the re-exploration rate was significantly reduced only by aprotinin. The risk of myocardial infarction or overall mortality was not increased by these drugs.
35. 35 Troianos C, Sypula R, Lucas D, D'Amico F, MathieT, Desai M, et al. The effect of prophylactic ε-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology 1999; 91:430-435 Prophylactic administration of ε-aminocaproic acid is of statistically significant but clinically minimal benefit for reducing blood loss postoperatively.
36. 36 Mongan PD, Brown RS, Thwaites BK. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg 1998; 87:258-265.
37. 37 Dietrich W. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998; 65:S60-S64. Data are presented on the incidence of adverse reactions to aprotinin and the time course of antibody development after initial exposure. Recommendations for reducing the risk and sequelae of these adverse reactions are emphasized and case reports are reviewed. The overall incidence rates of aprotinin-related reactions in patients with prior aprotinin treatment was 1.8% (eight out of 437). With the recommended precautions, re-exposure to aprotinin in patients with a high risk of bleeding is justified.
38. 38 Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg 1996; 62:1575-1577.
39. 39 Grocott HP, Sheng HX, Miura Y, SarrafYazdi S, Mackensen GB, Pearlstein RD, Warner DS. The effects of aprotinin on outcome from cerebral ischemia in the rat. Anesth Analg 1999; 88:1-7. This study determined whether aprotinin exhibits neuroprotective effects against either global or focal cerebral ischaemia in the rat. In this model aprotinin did not offer neuroprotection against cerebral ischaemia.
40. 40 Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R. Aprotinin enhances the endogenous release of Interleukin-IO after cardiac operations. Ann Thorac Surg 1998; 65:66-69.
41. 41 Alonso A, Whitten CW, Hill GE. Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation. Ann Thorac Surg 1999:67:392-395. The results of this study indicate that pump prime-only aprotinin (2 million KIU-Kallikrein-inhibiting units) modulates the CPB-induced upregulation of neutrophil CD11b integrin, an important indicator of the systemic inflammatory response to CPB. It is a piece in the puzzle of the anti-inflammatory properties of protease inhibitors during CPB.
42. 42 Gott JP, Cooper WA, Schmidt FE, Brown WM, Wright CE, Merlino JD, et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 1998; 66:747-753. Four state-of-the art anti-inflammatory strategies were studied in a prospective, randomized study comprising primary and reoperative cardiac surgery (n=400). Corticosteroids, aprotinin, leucocyte depletion, and heparin-bonded circuits were compared. Corticosteroids were given in all groups. These pharmacological and mechanical strategies attenuated the inflammatory response to CPB and translated into improved patient outcome. However, this response was not uniformly distributed, but rather was dependent on risk stratification.
43. 43 Wippermann CF, Schmid FX, Eberle B, Huth RG, Kampmann C, Schranz D, Oelert H. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Ann Thorac Surg 1999; 67:173-176. The haemodynamic effects of perioperative aprotinin treatment were investigated in a randomized, double-blind, placebo-controlled trial in 34 infants. Twelve hours after CPB 10 patients in the placebo group and four in the aprotinin group had received enoximone (P < 0.05). The placebo group had received significantly larger doses of enoximone than the aprotinin group on arrival in the intensive care unit. The placebo group required significantly more inotropic support by enoximone than the aprotinin group to achieve an equal haemodynamic status.
44. 44 McCarthy RJ, Turnan KJ, O'Connor C, Ivankovich AD. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs. Anesth Analg 1999; 89:1096-1100. This study has shown that aprotinin pretreatment diminishes postischaemic myocardial contractile dysfunction in dogs.
45. 45 Seghaye MC, Duchateau J, Grabitz RG, Jablonka K, Wenzl T, Marcus C, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 1996; 61:1205-1211.
46. 46 Segal H, Sheikh S, Kallis P, Cottam S, Beard C, Potter D, et al. Complement activation during major surgery: the effect of extracorporeal circuits and high-dose aprotinin. J Cardiothorac Vasc Anesth 1998; 12:542-547. This study compared complement activation in patients undergoing thoracic surgery (n=8), open heart surgery (n=19) and liver transplantation (n=19). Complement activation during cardiac surgery occurred to a greater extent than during liver transplantation or thoracic surgery. This activation was not attenuated by aprotinin.
47. 47 Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116:716-729. This study examined the effect of aprotinin on graft patency and perioperative myocardial infarction. This prospective, randomized, placebo-controlled, international, multicentre study showed varying results concerning graft patency, which overall occurred in 15.4% of the aprotinin-treated patients and in 10.9% of the control patients (P=0.03). The probability of vein graft occlusion was increased, but this outcome was promoted by multiple preoperative risk factors. Blood loss was reduced by aprotinin, and mortality and the occurrence of myocardial infarctions were equally distributed.
48. 48 Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999; 57:233-260. This is the latest overview of the aprotinin literature.
49. 49 Rich JB. The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg 1998; 66:S6-S11.
50. 50 Westaby S, Katsumata T. Aprotinin and vein graft occlusion: the controversy continues. J Thorac Cardiovasc Surg 1998; 116:731-733.